Cn /En

News Center

——

Company news

Industry news

PDX in vivo efficacy model of InnoModels Biotechnology

Author:

InnoModels

Release time:

2024-10-11

In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.
InnoModels Biotechnology: Leading in Technology, Innovating for the Future
Founded by scientists from Novo Nordisk China R&D Center, Sino-American Champion and the Institute of Immunology of Shanghai Jiao Tong University, InnoModels Biotechnology (Beijing) Co., Ltd. has been carrying the mission of promoting the research and development of oncology and oncology immunotherapeutics since the day of its birth. The company focuses on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services, and individualized healthcare, and is committed to providing new generation of experimental animal models close to the clinic for new drug discovery and development companies, translational medicine researchers, and tumor patients.
PDX in vivo pharmacodynamic model: a perfect blend of stability and efficacy
In the broad arena of oncology research, the PDX (Patient-Derived Xenograft) model has attracted much attention for its ability to highly mimic the biological characteristics of patients' tumors. Based on this, with profound scientific research strength and technological innovation, InnoModels Biotechnology has successfully created the PDX in vivo drug efficacy model, which provides a powerful tool for the development and evaluation of oncology drugs.
The model ensures the heterogeneity of tumor tissues and the complete retention of genomic information through primary cell inoculation technology, which makes the drug efficacy response and clinical consistency as high as over 90%. This breakthrough not only dramatically improves the success rate of modeling and the stability of experiments, but also enables the model to achieve uniform growth at an early stage, which lays a solid foundation for the smooth conduct of efficacy experiments.

Double guarantee of stability and efficacy
The uniqueness of InnoModels Bio's PDX in vivo potency model lies in its ability to homogenize samples from the same batch. The cell suspension modeling method ensures a high degree of consistency in growth rate and biological characteristics between samples in the same batch, thus guaranteeing the long-term stability of the model. This stability not only makes the experimental results more reliable, but also significantly reduces the experimental cost and improves the experimental efficiency.
In addition, the model has excellent scalability and can be combined with the PBMC (peripheral blood mononuclear cell) immune system humanization model to constitute a tumor-immune system dual humanization model. This innovative design provides a more comprehensive and realistic research platform for the development of new tumor immune drugs, and greatly promotes the research progress of tumor immunotherapy.
Practical application: rapid screening of DS-8201 drug resistance models
During the development of DS-8201 (fam-trastuzumab deruxtecan-nxki), a HER2-targeted ADC drug, InnoModels Biotechnology has successfully screened several HER2-positive DS-8201 resistance models with its efficient PDX model library. The discovery of these models not only provides valuable resources for the further development of HER2 ADC therapies, but also brings new hope for the treatment of DS-8201-resistant patients.
Conclusion
With its excellent stability, high efficiency and wide application prospects, the PDX in vivo drug efficacy model of InnoModels Biotechnology is gradually becoming an important force in the field of oncology and tumor immunology new drug development. In the days to come, we have reason to believe that InnoModels Biotechnology will continue to uphold the concept of technology leadership and innovation for the future, and contribute more wisdom and strength to the field of tumor therapy.

3D Organoid Platform of InnoModels Biotechnology: Opening a New Chapter in Life Science

InnoModels' CDX Modeling Platform: An Innovative Force for Cancer Research and Drug Development

3D Organoid Platform of InnoModels Biotechnology: Opening a New Chapter in Life Science

InnoModels' CDX Modeling Platform: An Innovative Force for Cancer Research and Drug Development

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License